Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    MA03 - Biomarkers for Immunotherapy: Are All Relevant?

    • 10:45 - 11:45
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
    • +

      MA03.02 - TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors

      10:50 - 10:55  |  Presenter: Edward B Garon

      • Abstract

      Loading...

  • +

    P11 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Clinical Trials in Progress

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
    • +

      P11.01 - Phase I Trial of in Situ Vaccination With Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined With Pembrolizumab for Advanced NSCLC

      00:00 - 00:00  |  Presenter: Edward B Garon

      • Abstract

      Loading...

  • +

    P50 - Novel Therapeutics and Targeted Therapies - EGFR Minor

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P50.01 - RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19-del Variants

      00:00 - 00:00  |  Presenter: Kazumi Nishino

      • Abstract

      Loading...

  • +

    PL02 - Plenary 2: Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)

    • 06:30 - 08:00
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PL02.01 - Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study

      06:30 - 06:40  |  Presenter: Melissa L Johnson

      • Abstract

      Loading...

  • +

    PL02A - Plenary 2: Presidential Symposium (Rebroadcast) (Japanese, Mandarin, Spanish Translation Available)

    • 14:30 - 16:00
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PL02A.01 - Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study

      14:30 - 14:40  |  Presenter: Melissa L Johnson

      • Abstract

      Loading...